Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Price
Data
About
GILD stock price forecast
News
Competitors
Tokenization
Crypto
FAQ
Gilead Sciences, Inc. stock logo

Gilead Sciences, Inc.

GILD·NASDAQ

Last updated as of 2026-02-10 23:26 EST. Stock price information is sourced from TradingView and reflects real-time market prices.

Insights
Calculator
News

GILD stock price change

On the last trading day, GILD stock closed at 149.96 USD, with a price change of -1.13% for the day.
Trade stock futures

About Bitget

The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more

GILD key data

Previous close149.96 USD
Market cap186.05B USD
Volume1.28M
P/E ratio23.23
Dividend yield (TTM)2.08%
Dividend amount0.79 USD
Last ex-dividend dateDec 15, 2025
Last payment dateDec 30, 2025
EPS diluted (TTM)6.46 USD
Net income (FY)480.00M USD
Revenue (FY)28.73B USD
Next report dateFeb 10, 2026
EPS estimate1.810 USD
Revenue estimate-
Shares float1.24B
Beta (1Y)0.17
Tokenized stocks

Have you heard of tokenized stocks?

A new way to trade stocks — anytime, anywhere, 24/7.

Learn more

Gilead Sciences, Inc. overview

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Sector
Health technology
Industry
Biotechnology
CEO
Daniel P. ODay
Headquarters
Foster City
Website
gilead.com
Founded
1987
Employees (FY)
17.6K
Change (1Y)
−400 −2.22%
Revenue / Employee (1Y)
1.63M USD
Net income / Employee (1Y)
27.27K USD

GILD Pulse

Daily updates on GILD stock prices, fund flows, and market news, generated by AI and reviewed by our team of analysts. Always DYOR.

• GILD Stock Price 24h change: -0.54%. From 152.50 USD to 151.68 USD. (Note: Prices reflect the most recent trading session prior to the Q4 2025 earnings release on Feb 10).
• From a technical perspective, the market shows a "strong bullish trend with overbought caution": price remains well above the 50-day and 200-day SMAs, indicating powerful long-term momentum; however, the RSI is near 82, signaling a potential short-term pullback or consolidation as the stock is technically overbought.
• Gilead Sciences reported Q4 2025 revenue of $7.9 billion, up 5% year-over-year, driven by HIV and Liver Disease sales, including the successful launch of its twice-yearly HIV prevention drug Yeztugo.
• The FDA approved a label update for Kite’s (a Gilead company) Yescarta, removing usage limitations for relapsed/refractory primary central nervous system lymphoma, expanding its treatment reach.
• Positive Phase 3 data published in the New England Journal of Medicine supports Trodelvy plus Keytruda as a potential new first-line standard of care for metastatic triple-negative breast cancer.
• Amgen reported Q4 revenue growth of 8.6%, signaling a robust environment for large-cap therapeutics despite broader biotech volatility throughout 2025.
• The White House debuted "TrumpRx," an online service for discounted drug sales, sparking industry-wide discussions on long-term drug pricing impacts and federal healthcare policy shifts.
See more
about 12h ago
• GILD Stock Price 24h change: +2.10%. From 149.37 USD to 152.50 USD. The price surge is driven by positive market anticipation ahead of the Q4 2025 earnings report and recent FDA label expansions for its oncology portfolio.
• From a technical perspective, the stock is in a "Strong Buy" phase with significant bullish momentum: GILD is trading above its 50-day ($127.52) and 200-day ($116.77) moving averages. However, the 14-day RSI is at 74.16, indicating the stock is entering overbought territory and may face short-term consolidation.
• The FDA approved an update to Yescarta’s prescribing information, removing prior use limitations for primary central nervous system lymphoma, making it the only CAR T-cell therapy with this expanded label.
• Gilead is scheduled to release its Q4 2025 earnings on February 10, 2026, with analysts forecasting $1.87 EPS and $7.68 billion in revenue following a strong year for its HIV and oncology franchises.
• Phase 3 data published in the NEJM showed that Trodelvy combined with Keytruda significantly reduced the risk of disease progression by 35% in first-line metastatic triple-negative breast cancer.
• Eli Lilly announced a $2.4 billion acquisition of Orna Therapeutics to enter the in vivo CAR-T therapy space, reflecting a continued industry-wide push into advanced cell and gene therapies.
• The FDA launched a new "PreCheck" pilot program to accelerate the construction and regulatory review of domestic drug manufacturing facilities to strengthen the U.S. pharmaceutical supply chain.
See more
about 1D ago

GILD stock price forecast

According to technical indicators for GILD stock, the price is likely to fluctuate within the range of 147.25–176.79 USD over the next week. Market analysts predict that the price of GILD stock will likely fluctuate within the range of 141.42–180.97 USD over the next months.

Based on 1-year price forecasts from 85 analysts, the highest estimate is 387.07 USD, while the lowest estimate is 146.16 USD.

For more information, please see the GILD stock price forecast Stock Price Forecast page.

Latest GILD stock news

AbbVie secures agreement with the Trump administration on medication pricing in return for tariff reductions

101 finance2026-01-13 09:24:29

Factbox-Global drugmakers rush to boost US presence as tariff threat looms

101 finance2026-01-13 13:21:24

Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade

101 finance2026-01-15 12:24:24

Gilead Sciences Earnings Outlook: Key Points to Watch

101 finance2026-01-19 16:21:33

BMO Capital raises Gilead Sciences' target price to $150

格隆汇2026-01-27 07:45:54

Truist raises Gilead Sciences' target price to $145

格隆汇2026-01-28 08:22:01

What’s Ahead in the Markets This Week: January Employment Figures, Updates on Inflation and Retail Sales; Earnings Releases from Cisco, Coca-Cola, and McDonald’s

101 finance2026-02-08 11:09:11

Dow 50,000 milestone puts focus on inflation figures and postponed January employment data: Key events to monitor this week

101 finance2026-02-08 12:42:39

Gilead: Fourth Quarter Earnings Overview

101 finance2026-02-10 21:21:36

Gilead Sciences (NASDAQ:GILD) reported fourth quarter 2025 sales that surpassed expectations

101 finance2026-02-10 21:27:37

Gilead Sciences outlines its outlook for fiscal year 2026 in its latest report.

老虎证券2026-02-10 22:21:45

Gilead's 2026 Outlook Falls Short of Wall Street Expectations, Stock Price Drops

新浪财经2026-02-10 23:29:08

US Stocks Move | Gilead Sciences drops 1.8% in after-hours trading as this year's product sales and profit guidance fall short of expectations

格隆汇2026-02-11 02:15:01

With just a Bitget account, you can trade stocks and cryptocurrencies at the same time.

Join now!

FAQ

What is the stock price of Gilead Sciences, Inc.?

GILD is currently priced at 149.96 USD — its price has changed by -1.13% over the past 24 hours. You can track the stock price performance of Gilead Sciences, Inc. more closely on the price chart at the top of this page.

What is the stock ticker of Gilead Sciences, Inc.?

Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ, Gilead Sciences, Inc. is traded under the ticker GILD.

What is the stock forecast of GILD?

We've gathered analysts' opinions on Gilead Sciences, Inc.'s future price. According to their forecasts, GILD has a maximum estimate of 1499.60 USD and a minimum estimate of 299.92 USD.

What is the market cap of Gilead Sciences, Inc.?

Gilead Sciences, Inc. has a market capitalization of 186.05B USD.

What is P/E ratio (TTM)?

The P/E ratio (TTM) stands for price-to-earnings ratio (trailing twelve months). It is a historical valuation metric calculated using a company's earnings per share (EPS) over the most recent twelve consecutive months, reflecting the company's past profitability.

The P/E ratio measures the relationship between a stock's price and a company's profitability, and is often used as a basis for judging whether a stock is "cheap" or "expensive."

P/E ratio = market price (P) ÷ earnings per share (EPS), or P/E ratio = total market capitalization ÷ net profit attributable to shareholders

The interpretation of the P/E ratio (TTM) should always be considered alongside other factors and is mainly used for valuation comparisons rather than as a standalone indicator.

  • A lower P/E ratio (TTM) means investors are paying less for each unit of earnings. This may indicate that the stock is undervalued, or that the market has limited expectations for the company's future growth, such as in mature or slow-growing industries.
  • A higher P/E ratio (TTM) means investors are paying more for each unit of earnings. This often reflects expectations of strong future earnings growth, which is common among growth or technology stocks, though it may also suggest the stock is overvalued.
  • Comparison with peers: Compare the company's P/E (TTM) with the average or median P/E of other companies in the same industry. A significantly higher P/E may require further analysis to determine whether the company's high valuation is justified by stronger growth prospects or competitive advantages.
  • Comparison with historical levels: Compare the company's current P/E (TTM) with its own historical average (such as over the past 5 or 10 years) to assess whether the current valuation is at a historical high or low.
  • Comparison with the broader market: Compare the company's P/E (TTM) with major market indices (such as the S&P 500) to see how the market is valuing the company overall.

P/E ratios can vary widely across industries, and there is no single "ideal" P/E level. A reasonable P/E range depends on the industry, the company's growth potential, and the broader macroeconomic environment. Investment decisions should not rely solely on the P/E ratio (TTM) but should be based on a comprehensive analysis that includes company quality, growth prospects, and financial health.

Can I trade stocks on Bitget?

You can trade stocks on Bitget, but mainly through stock tokens and stock perps, rather than by directly buying or selling traditional stocks.

This approach reflects Bitget's vision as a Universal Exchange (UEX), designed to connect traditional financial markets with cryptocurrency markets.

Bitget currently offers the following stock-related trading formats:

1. Stock tokens (spot)

Nature: Stock tokens are digital tokens pegged to the price of specific traditional stocks (such as TSLAUSDT and NVDAUSDT) and are traded on Bitget's spot market.

Features: When you trade stock tokens, you are buying and holding tokens rather than owning the underlying traditional stocks.

  • The price of these tokens generally follows the price movements of the stocks they are pegged to, such as Tesla or Nvidia.
  • The advantage is that you can participate in the price movements of traditional financial assets, such as U.S. stocks, using cryptocurrencies (for example, USDT), without the need for a traditional brokerage account.

2. Stock perps

Nature: Bitget also offers USDT-margined perpetual futures, commonly referred to as stock perps, based on major U.S. blue-chip stocks such as Tesla and Meta.

Characteristics: Stock perps are derivative products that allow you to take a bullish or bearish view on the future price of an underlying stock through margin trading. These products typically support leverage, such as up to 25x.

It does not involve owning the underlying stock. Instead, profits and losses are settled based on price movements of the futures.

Important note: When trading stock perps on Bitget, you are participating in derivative markets within the cryptocurrency ecosystem. This is fundamentally different from purchasing publicly traded shares through a traditional brokerage, as you do not own equity in the underlying company.

Futures trading and the use of leverage involve high risk. Please ensure you fully understand the risks before trading.

If you wish to directly hold equity in traditional stocks and enjoy shareholder rights (such as receiving dividends), you must trade through a regulated traditional securities brokerage or brokerage platform.

What are the advantages of Bitget's stock perps?

Bitget's stock perps—typically perpetual futures based on stock tokens prices—are an innovative offering that allows cryptocurrency platforms to provide exposure to traditional financial markets.

Compared to traditional stock or futures trading, they offer several unique advantages, primarily due to the platform's trading infrastructure.

Bitget's stock perps, typically USDT-denominated derivatives, offer the following key advantages:

1. Trading convenience and global accessibility

  • 24/7 trading: Traditional stock markets, such as U.S. equity markets, operate during fixed trading hours. In contrast, cryptocurrency derivatives markets are typically open 24/7. This means investors can trade anytime, capitalizing on breaking news or market fluctuations.
  • Lower entry barriers and faster onboarding: Compared with traditional brokerages, which often require extensive identity verification and lengthy account setup processes, Bitget generally offers faster account onboarding. Users can trade using cryptocurrencies such as USDT, without the need for complex fiat deposit and withdrawal procedures.
  • Global accessibility: Users can access derivatives trading linked to globally recognized stocks via the Bitget platform, subject to applicable regulations.

2. Capital efficiency and high leverage

  • High leverage options: Stock perps typically offer higher leverage than traditional stock trading (for example, up to 25x). This allows traders to control larger positions with smaller margin requirements, improving capital efficiency.
    Note: While high leverage can amplify gains, it also amplifies losses proportionally.
  • Two-way trading: Traders can easily take both long and short positions. This means traders can potentially profit from market volatility whether stock prices rise or fall, provided the market direction is correctly anticipated.

3. Trading and settlement using cryptocurrency

  • USDT margin: Stock perps on Bitget typically use USDT (or other stablecoins) as the margin and settlement currency. For users who already hold cryptocurrency, there is no need to convert assets into fiat currency, allowing them to trade directly with stablecoins.
  • Efficient fund transfers: Crypto-based transfers and settlements are typically faster than traditional fiat systems, enabling more efficient global fund allocation.

4. Integration

One-stop platform: Bitget allows users to trade spot cryptocurrencies, crypto derivatives, and stock perps on a single platform, making it easier to manage different asset types in one place.

Risk warning:

While Bitget's stock perps offer several advantages, it is important to understand the associated risks.

  • High leverage risk: Leveraged trading can result in rapid loss of your entire margin.
  • No equity ownership: When trading stock perps, you do not own the underlying shares. As a result, you are not entitled to dividends or voting rights.
  • Market liquidity risk: Tokenized stock perps may have lower liquidity than their counterparts in traditional stock markets, especially outside regular trading hours.

In summary, Bitget's stock perps offer advantages such as greater trading flexibility, lower entry barriers, and higher capital efficiency.

What are the trading fees for Bitget stock perps?

Trading fees for Bitget stock perps (USDT-margined perpetual futures) mainly include transaction fees and funding rates.

Transaction fees:

Bitget offers limited-time fee promotions for stock perps (especially tokenized stock perps) from time to time to attract traders.

Standard reference rates: Under Bitget's standard futures fee structure, the taker fee is typically around 0.06%, while the maker fee is around 0.02%.

Current promotions for stock perps (important): To promote its stock perps products, Bitget is offering discounted transaction fees during Q4 2025, with taker fees as low as 0.006% and maker fees as low as 0.002%. There is also a limited-time promotion offering zero-fee trading for spot stock tokens.

Recommendation: Since promotional activities are subject to change or end at any time, please visit Bitget's official Fee overview or Announcement Center page for the latest and most accurate rates at the time of trading.

Funding rate:

The funding rate is a key mechanism in perpetual futures (including stock perps) that helps keep the futures price closely aligned with the spot price of the underlying asset. It is not a fee charged by the platform, but a periodic payment exchanged between long and short traders.

Funding rates fluctuate dynamically and are mainly driven by market sentiment and imbalances between long and short positions. Stock perps generally experience lower volatility than cryptocurrencies, so funding rates are often relatively low during stable market conditions. However, during earnings seasons or major positive or negative news events, heavy concentration of long or short positions—such as in high-growth technology stocks like Tesla or Nvidia—can create significant imbalances, causing funding rates to spike in the short term.

Funding payments are typically settled every 8 hours. If you close your position before the funding settlement time, no funding payment will be charged or received.

Funding rates are not fixed. If you hold a position for an extended period, high positive funding rates (for long positions) or high negative funding rates (for short positions) will affect your overall holding costs or potential returns. For this reason, it is important to monitor the funding rate in real time on the trading interface.

NASDAQ/
GILD